

Lonza
"Pioneer in contract development and manufacturing of breakthrough medicines"
About Lonza
Lonza is a contract development and manufacturing organisation (CDMO) serving the healthcare industry. Founded in 1897 in Switzerland, the company partners with biotech and pharmaceutical firms to transform breakthrough innovations into viable therapies. Lonza delivers services from early development to commercial manufacturing of biologics, small molecules, APIs, mRNA, and cell and gene therapies. With over 30 sites and 20,000 colleagues across five continents, Lonza brings life-saving treatments to patients worldwide. The company combines cutting-edge science, smart technology, and lean production expertise to meet pharmaceutical and biotech demands. Publicly traded on the SIX Swiss Exchange, Lonza is a pioneer in the CDMO industry.


20000
Team Members
1897
Founded
Public
Funding
Hybrid
Work Environment
A world where breakthrough medical innovations reach patients faster through seamless collaboration between science, technology and manufacturing expertise.
Lonza turns customers' breakthrough innovations into viable therapies and manufactures the medicines of tomorrow.